-
Seasoned Litigator
T.O. is a trial lawyer who focuses on patent infringement actions with a particular emphasis on representing prominent generic pharmaceutical companies in Hatch-Waxman Act litigation.
-
Experience Litigating Matters in Federal Court Across the U.S.
T.O. has substantial experience in federal district courts including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, and Northern California.
-
Thought Leadership
T.O. has been asked to speak at national conferences regarding Paragraph IV Disputes and has presented on at-risk launches, preliminary injunctions, and the generic perspective on initial stages of a Paragraph IV lawsuit.
T.O. Kong is a trial lawyer in Wilson Sonsini Goodrich & Rosati's litigation department. He focuses on life science patent infringement actions, with a particular emphasis on the representation of prominent pharmaceutical companies in Hatch-Waxman Act and biosimilar litigation.
LMG Life Sciences shortlisted T.O. for “Hatch-Waxman Litigator of the Year (Generic)” in 2024 and "Appellate Litigator of the Year: Intellectual Property" in 2022.
T.O. has substantial courtroom experience in federal courts across the country, including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, Northern California and the Federal Circuit.
T.O. Kong is a trial lawyer in Wilson Sonsini Goodrich & Rosati's litigation department. He focuses on life science patent infringement actions, with a particular emphasis on the representation of prominent pharmaceutical companies in Hatch-Waxman Act and biosimilar litigation.
LMG Life Sciences shortlisted T.O. for “Hatch-Waxman Litigator of the Year (Generic)” in 2024 and "Appellate Litigator of the Year: Intellectual Property" in 2022.
T.O. has substantial courtroom experience in federal courts across the country, including Delaware, New Jersey, Southern New York, Eastern New York, Northern Illinois, Western Wisconsin, Eastern Texas, Central California, Northern California and the Federal Circuit.
- J.D., Tulane Law School, 1999Magna Cum Laude; Managing Editor, Tulane Maritime Law Journal; Judicial Extern with the United States District Court for the Eastern District of Louisiana to the Honorable Sara S. Vance
- B.A., University of California, San Diego, 1993
- Member, American Bar Association
- Member, Association of Business Trial Lawyers
- Member, Bar Association of San Francisco
- Named a finalist for “Hatch-Waxman Litigator of the Year (Generic)” for the LMG Life Sciences 2024 Americas Awards
- Recognized by Patexia as one of the best performing ANDA attorneys overall in its 2023 ANDA Litigation Intelligence Report
- Named a finalist for "Appellate Litigator of the Year: Intellectual Property" for the LMG Life Sciences 2022 Americas Awards
- State Bar of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Northern District of California
- U.S. Court of Appeals for the Federal Circuit
- J.D., Tulane Law School, 1999Magna Cum Laude; Managing Editor, Tulane Maritime Law Journal; Judicial Extern with the United States District Court for the Eastern District of Louisiana to the Honorable Sara S. Vance
- B.A., University of California, San Diego, 1993
- Member, American Bar Association
- Member, Association of Business Trial Lawyers
- Member, Bar Association of San Francisco
- Named a finalist for “Hatch-Waxman Litigator of the Year (Generic)” for the LMG Life Sciences 2024 Americas Awards
- Recognized by Patexia as one of the best performing ANDA attorneys overall in its 2023 ANDA Litigation Intelligence Report
- Named a finalist for "Appellate Litigator of the Year: Intellectual Property" for the LMG Life Sciences 2022 Americas Awards
- State Bar of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Northern District of California
- U.S. Court of Appeals for the Federal Circuit
Select Representations
T.O. has successfully served as lead counsel in disputes regarding the following pharmaceutical products:
- Esbriet (pirfenidone)
- Cinvanti (aprepitant)
- Aponvie (aprepitant)
- Trulance (plecanatide)
- Epaned (enalapril)
- Firvanq (vancomycin)
- Injectafer (ferric carboxymaltose)
- Auryxia (ferric citrate)
- Pomalyst (pomalidomide)
- Revlimid (lenalidomide)
- Jublia (efinaconazole)
- Kerydin (tavaborole)
- Suboxone (buprenorphine/naloxone sublingual film)
- Minivelle (estradiol transdermal patch)
- Ultiva (remifentanil for injection)
- Cialis (tadalafil)
- Adcirca (tadalafil)
- Gilenya (fingolimod)
- Brevibloc (esmolol)
- Lidoderm (lidocaine transdermal patch)
- Zometa (zoledronic acid infusion)
- Reclast (zoledronic acid infusion)
- Daytrana (methylphenidate transdermal patch)
- Viagra (sildenafil)
- Velcade (bortezomib)
- Daliresp (roflumilast)
- Pradaxa (dabigatran)
- Doryx (doxycycline)
- Oracea (doxycycline)
- Uloric (febuxostat)
- Banzel (rufinamide)
- Focalin (dexmethylphenidate)
- Actoplus Met XR (pioglitazone/metformin)
- Lescol XL (fluvastatin)
- Vivelle-Dot (estradiol transdermal patch)
- Lunesta (eszopiclone)
Select Representations
T.O. has successfully served as lead counsel in disputes regarding the following pharmaceutical products:
- Esbriet (pirfenidone)
- Cinvanti (aprepitant)
- Aponvie (aprepitant)
- Trulance (plecanatide)
- Epaned (enalapril)
- Firvanq (vancomycin)
- Injectafer (ferric carboxymaltose)
- Auryxia (ferric citrate)
- Pomalyst (pomalidomide)
- Revlimid (lenalidomide)
- Jublia (efinaconazole)
- Kerydin (tavaborole)
- Suboxone (buprenorphine/naloxone sublingual film)
- Minivelle (estradiol transdermal patch)
- Ultiva (remifentanil for injection)
- Cialis (tadalafil)
- Adcirca (tadalafil)
- Gilenya (fingolimod)
- Brevibloc (esmolol)
- Lidoderm (lidocaine transdermal patch)
- Zometa (zoledronic acid infusion)
- Reclast (zoledronic acid infusion)
- Daytrana (methylphenidate transdermal patch)
- Viagra (sildenafil)
- Velcade (bortezomib)
- Daliresp (roflumilast)
- Pradaxa (dabigatran)
- Doryx (doxycycline)
- Oracea (doxycycline)
- Uloric (febuxostat)
- Banzel (rufinamide)
- Focalin (dexmethylphenidate)
- Actoplus Met XR (pioglitazone/metformin)
- Lescol XL (fluvastatin)
- Vivelle-Dot (estradiol transdermal patch)
- Lunesta (eszopiclone)
Wilson Sonsini partner T.O. Kong argued the case at the PTAB and the Federal Circuit, with support from Tasha Thomas, Lori Westin, Rick Torczon, Kathryn Robinson, and Robyn Moriarty.
- Privacy Policy
- Terms of Use
- Accessibility